Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2014
Measles vaccination in the presence or absence of maternal measles antibody: impact on child survival.
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Measles Vaccination in Guinea-Bissau. Strategies to Reduce Disease Burden and Improve Child Survival
Randomized Trial Evaluating the Non-specific Effects of Different BCG Strains in Guinea-Bissau: Effects on Early-life Mortality and Morbidity
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 110 citations in OpenAlex.
- Measles vaccines and non-specific effects on mortality or morbidity: A systematic review and meta-analysis.PloS one · 2025Pooled it
- Revaccination with Live Attenuated Vaccines Confer Additional Beneficial Nonspecific Effects on Overall Survival: A Review.EBioMedicine · 2016Pooled it
- Measles, mumps, and rubella vaccine at age 6 months and hospitalisation for infection before age 12 months: randomised controlled trial.BMJ (Clinical research ed.) · 2023Trial
- Sex and prior exposure jointly shape innate immune responses to a live herpesvirus vaccine.eLife · 2023Trial
- The Effect of a Second Dose of Measles Vaccine at 18 Months of Age on Nonaccidental Deaths and Hospital Admissions in Guinea-Bissau: Interim Analysis of a Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Effects of Bacillus Calmette-Guérin (BCG) vaccination at birth on T and B lymphocyte subsets: Results from a clinical randomized trial.Scientific reports · 2017Trial
- Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau.The Journal of infectious diseases · 2017Trial
- BCG vaccination at birth and early childhood hospitalisation: a randomised clinical multicentre trial.Archives of disease in childhood · 2017Trial
- Trial
- Nonspecific effect of BCG vaccination at birth on early childhood infections: a randomized, clinical multicenter trial.Pediatric research · 2016Trial
- The origin of non-specific effects of vaccines and the role of randomised clinical trials.Human vaccines & immunotherapeutics · 2026Review
- Trained Immunity in Childhood Vaccination.Acta paediatrica (Oslo, Norway : 1992) · 2026Review
- Maternal Influenza Vaccine Reduces the Risk of Respiratory Syncytial Virus and Related Respiratory Hospitalizations in Early Infancy: An Epidemiological Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Bacille Calmette-Guérin-specific IgG titres among infants born to mothers with active tuberculosis disease in Uganda.BMC immunology · 2025Article
- Prenatal Maternal Immunization for Infant Protection: A Review of the Vaccines Recommended, Infant Immunity and Future Research Directions.Pathogens (Basel, Switzerland) · 2024Review
- Beneficial non-specific effects of live vaccines against COVID-19 and other unrelated infections.The Lancet. Infectious diseases · 2023Review
- Effect of early two-dose measles vaccination on childhood mortality and modification by maternal measles antibody in Guinea-Bissau, West Africa: A single-centre open-label randomised controlled trial.EClinicalMedicine · 2022Article
- Parental Bacillus Calmette-Guérin vaccine scars decrease infant mortality in the first six weeks of life: A retrospective cohort study.EClinicalMedicine · 2021Article
- The Protective Role of Maternal Immunization in Early Life.Frontiers in pediatrics · 2021Review
- Single Immunization of a Vaccine Vectored by a Novel Recombinant Vaccinia Virus Affords Effective Protection Against Respiratory Syncytial Virus Infection in Cotton Rats.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMeasles vaccine (MV) has a greater effect on child survival when administered in early infancy, when maternal antibody may still be present.
methodsTo test whether MV has a greater effect on overall survival if given in the presence of maternal measles antibody, we reanalyzed data from 2 previously published randomized trials of a 2-dose schedule with MV given at 4-6 months and at 9 months of age. In both trials antibody levels had been measured before early measles vaccination.
resultsIn trial I (1993-1995), the mortality rate was 0.0 per 1000 person-years among children vaccinated with MV in the presence of maternal antibody and 32.3 per 1000 person-years without maternal antibody (mortality rate ratio [MRR], 0.0; 95% confidence interval [CI], 0-.52). In trial II (2003-2007), the mortality rate was 4.2 per 1000 person-years among children vaccinated in presence of maternal measles antibody and 14.5 per 1000 person-years without measles antibody (MRR, 0.29; 95% CI, .09-.91). Possible confounding factors did not explain the difference. In a combined analysis, children who had measles antibody detected when they received their first dose of MV at 4-6 months of age had lower mortality than children with no maternal antibody, the MRR being 0.22 (95% CI, .07-.64) between 4-6 months and 5 years.
conclusionsChild mortality in low-income countries may be reduced by vaccinating against measles in the presence of maternal antibody, using a 2-dose schedule with the first dose at 4-6 months (earlier than currently recommended) and a booster dose at 9-12 months of age. CLINICAL TRIALS REGISTRATION: NCT00168558.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.